Home ›
Gastric Cancer Trials ›
NCT06792162
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.
Trial Details
NCT ID NCT06792162
Phase PHASE2
Sponsor Peking University Third Hospital
Status RECRUITING
Cancer Type Gastric Cancer
Interventions
Locations (sample) Beijing, China|39.9075,116.39723
Key Eligibility Criteria
Age greater than or equal to 18 years old, gender not limited; Histologically confirmed unresectable stage III and IV dMMR (complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6), gastric adenocarci… Unresectable gastric cancer patients with potential for conversion therapy, defined as gastric cancer patients with single organ metastasis (such a… Without surgery, radiation therapy, or immunotherapy for the gastric cancer lesion or metastatic tumor.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Gastric Cancer Trials on Trialify →